CUMULUS ONCOLOGY LIMITEDActive
Key figures
Like most small UK companies, CUMULUS ONCOLOGY LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.
Balance sheet structure
Filed accounts2019/20–2025
| 2019/20 | 2020/21 | 2022/23 | 2025 | |
|---|---|---|---|---|
| Cash at bank and in hand | — | 1,057,532 | 1,678,915 | 120,075 |
| Total assets | 159 | 1,118,755 | 3,005,067 | — |
| Total liabilities | — | 44,680 | 136,503 | — |
| Net assets / total equity | 159 | 1,074,075 | 2,868,564 | 3,191,532 |
| Average number of employees | 0 | 4 | 10 | 15 |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
Principal activity
Accounts 2025Cumulus Oncology Limited is a private company limited by shares, registered in Scotland. The address of the registered office and registration number are as below:
As described in the company's latest filed accounts.
Summary: CUMULUS ONCOLOGY LIMITED
Company
CUMULUS ONCOLOGY LIMITED is a private limited company registered with Companies House under company number SC581311. It was incorporated on 13 Nov 2017. Its status is active. The registered office is in Edinburgh (EH3). Its nature of business (SIC 2007) is research and experimental development on biotechnology (72110), other research and experimental development on natural sciences and engineering (72190).
Accounts
The latest accounts in the database are for 2025 (period ending 31 Dec 2025); the company files small company accounts (filleted). Net assets were £3,191,532, up 11.3% on the previous year. Cash at bank and in hand was £120,075. The company had an average of 15 employees. Figures are available for 4 financial years (2019/20–2025).
Control and charges
One person with significant control is registered. 1 of 1 registered charges are outstanding.
Filing deadlines
The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 26 Nov 2026.